PACIRA PHARMACEUTICALS INC's ticker is PCRX and the CUSIP is 695127100. A total of 254 filers reported holding PACIRA PHARMACEUTICALS INC in Q3 2023. The put-call ratio across all filers is 0.88 and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $4,818,662 | +2165.1% | 157,062 | +2858.4% | 0.01% | – |
Q2 2023 | $212,732 | -72.6% | 5,309 | -72.1% | 0.00% | -100.0% |
Q1 2023 | $776,696 | -12.6% | 19,032 | +63.4% | 0.00% | 0.0% |
Q1 2022 | $889,000 | -70.3% | 11,651 | -76.6% | 0.00% | -50.0% |
Q4 2021 | $2,990,000 | -33.0% | 49,697 | -37.7% | 0.00% | -50.0% |
Q3 2021 | $4,465,000 | -54.7% | 79,733 | -50.9% | 0.00% | -55.6% |
Q2 2021 | $9,862,000 | -76.5% | 162,523 | -72.8% | 0.01% | -77.5% |
Q1 2021 | $41,951,000 | -18.3% | 598,529 | -30.2% | 0.04% | -13.0% |
Q4 2020 | $51,340,000 | -2.1% | 857,956 | -1.6% | 0.05% | -14.8% |
Q3 2020 | $52,445,000 | +3.0% | 872,332 | -10.1% | 0.05% | -11.5% |
Q2 2020 | $50,916,000 | +45.0% | 970,385 | -7.3% | 0.06% | +10.9% |
Q1 2020 | $35,105,000 | -31.3% | 1,046,983 | -7.2% | 0.06% | -5.2% |
Q4 2019 | $51,098,000 | +9.3% | 1,128,008 | -8.1% | 0.06% | 0.0% |
Q3 2019 | $46,740,000 | -13.9% | 1,227,740 | -1.7% | 0.06% | -14.7% |
Q2 2019 | $54,301,000 | +51.4% | 1,248,573 | +32.5% | 0.07% | +47.8% |
Q1 2019 | $35,870,000 | +124.0% | 942,444 | +153.2% | 0.05% | +109.1% |
Q4 2018 | $16,012,000 | +99.8% | 372,207 | +128.3% | 0.02% | +120.0% |
Q3 2018 | $8,013,000 | +1211.5% | 163,037 | +731.1% | 0.01% | +900.0% |
Q1 2018 | $611,000 | -51.4% | 19,616 | -28.7% | 0.00% | 0.0% |
Q4 2017 | $1,256,000 | +239.5% | 27,500 | +179.2% | 0.00% | 0.0% |
Q3 2017 | $370,000 | -95.5% | 9,851 | -90.7% | 0.00% | -91.7% |
Q4 2015 | $8,175,000 | +101.6% | 106,462 | +7.9% | 0.01% | +100.0% |
Q3 2015 | $4,055,000 | +8.2% | 98,664 | +133.8% | 0.01% | 0.0% |
Q1 2015 | $3,749,000 | -28.1% | 42,198 | -28.3% | 0.01% | 0.0% |
Q4 2014 | $5,215,000 | -24.4% | 58,822 | -17.4% | 0.01% | -33.3% |
Q3 2014 | $6,901,000 | -36.1% | 71,200 | -39.4% | 0.01% | -35.7% |
Q2 2014 | $10,801,000 | +1.9% | 117,582 | -22.4% | 0.01% | -6.7% |
Q1 2014 | $10,599,000 | +89.2% | 151,439 | +55.4% | 0.02% | +114.3% |
Q4 2013 | $5,602,000 | +1.9% | 97,456 | -14.7% | 0.01% | -22.2% |
Q3 2013 | $5,498,000 | -23.7% | 114,310 | -54.0% | 0.01% | -30.8% |
Q2 2013 | $7,210,000 | – | 248,636 | – | 0.01% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Gagnon Advisors, LLC | 251,140 | $19,167,000 | 8.83% |
GAGNON SECURITIES LLC | 610,933 | $46,626,000 | 7.60% |
Tamarack Advisers, LP | 205,000 | $15,646,000 | 7.40% |
Spyglass Capital Management LLC | 1,871,040 | $142,798,000 | 4.88% |
Lisanti Capital Growth, LLC | 302,413 | $23,080,000 | 2.59% |
Rock Springs Capital Management LP | 1,000,000 | $76,320,000 | 1.92% |
MESIROW FINANCIAL INVESTMENT MANAGEMENT - Fixed Income | 208,197 | $15,890,000 | 1.76% |
JABODON PT CO | 49,052 | $3,744,000 | 1.70% |
Zweig-DiMenna Associates LLC | 166,675 | $12,721,000 | 1.70% |
NEUMEIER POMA INVESTMENT COUNSEL LLC | 317,425 | $24,226,000 | 1.63% |